510(k) Clearance of Blockade Medical’s Barricade Coil System

Blockade Medical L.L.C.’s Barricade Coil System, a medical device, has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) and that the first series of clinical cases treated with the Barricade Coil System in the United States has been successfully completed.

Rush University Medical Center in Chicago, Ill., was the first center in the United States to use the Barricade Coil System.

“We are very pleased to have received FDA clearance for the Barricade Coil system. This is a significant achievement as we continue the successful commercialization of the Barricade Coil System. The initial clinical feedback in the United States reinforces the positive feedback from our international experience and we look forward to impacting patient lives in a positive way,” said Gibb Clarke, Blockade Medical’s CEO.

The Barricade Coil System is an embolization coil line that is designed to endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels. The Barricade Coil System is a comprehensive bare platinum coil line available in framing, filling and finishing shapes. The Barricade Coil System received CE Mark in July 2012.